Skip to content

calculation of serum hepcidin levels in oral submucous fibrosis.

Evaluation of serum Hepcidin in Oral Submucous Fibrosis - OSMF

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2016/03/006761
Enrollment
80
Registered
2016-03-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx Health Condition 2: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx Health Condition 3: null- Patients with Oral Submucous Fibrosis of Different grades including with dysplasia

Interventions

None listed

Sponsors

Rajiv Gandhi University of Health Sciences
Lead Sponsor
Sri Rajiv Gandhi College of Dental Sciences and Hospital
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Male and female patients with different grades of Oral Submucous Fibrosis including that with dysplastic changes

Exclusion criteria

Exclusion criteria: Patients who are systemically ill with chronic inflammatory diseases and patients who have laready been treated for OSMF and are on antioxdiant medications

Design outcomes

Primary

MeasureTime frame
Hepcidin levels with varying degrees of OSMFTimepoint: At baseline that is at the start of the study

Secondary

MeasureTime frame
varying levels of hepcidin in OSMF with dysplasiaTimepoint: At the end of 3 months

Countries

India

Contacts

Public ContactDr HNSantosh

Sri Rajiv Gandhi College of Dental Sciences and Hospital

drhnsantosh29@yahoo.co.in9448721428

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 23, 2026